In comparison, previous studies in Central Europe showed that LRRK2 pathogenic variants are quite rare within PD cohorts, with the p.G2019S variant’s combined prevalence being reported as only 0.33% (MAF = 0.00164) [20]. This evidence concerns the gene LRRK2 and Parkinson disease.